Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "cell-penetrating peptides" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Peptydy penetrujące : rodzaje i mechanizmy przenikania przez błony komórkowe
Cell-penetrating peptides : types and mechanisms of penetration
Autorzy:
Kawczyński, M. T.
Kreczko-Kurzawa, J.
Maćkiewicz, Z.
Powiązania:
https://bibliotekanauki.pl/articles/172725.pdf
Data publikacji:
2015
Wydawca:
Polskie Towarzystwo Chemiczne
Tematy:
peptydy penetrujące
penetratyna
endocytoza
amfipatyczność
CPP
cell-penetrating peptides
penetratin
endocytosis
amphipaticity
Opis:
Before discovery of the Tat peptide over twenty years ago, it was assumed that large peptides and proteins do not penetrate cell membranes. After discovery of Tat, Penetratin [1, 2] and several other peptides of natural origin, able to cross the cell membranes in an energy-independent manner, the structural determinants of their cell-penetrating potency were established, including polycationic character, amphipaticity and presence of proline-rich motifs [3, 4]. Currently known cell-penetrating peptides of natural or synthetic origin are composed of 5 to 40 amino acid residues and belong to one of the three families: oligocationic, amphipatic or proline-rich and penetrate the biological membranes by endocytosis or other ways of direct translocation. Most of these translocation mechanisms are not exclusive and may occur simultaneously, and their contribution may be different for each peptide depending on the conditions (e.g. CPP concentration, pH, etc.). Most CPPs demonstrate little or no mammalian cell toxicity what makes them promising vectors for drug delivery. Such vectors might be useful for efficient internalization of compounds otherways poorly penetrating biological membranes. Novel CPP-effector conjugates may become effective anticancer or antimicrobial agents of a great potential for chemotherapy [3, 5]. In this short review we present a glimpse at the current state of knowledge concerning sub‑families, types and mechanisms of action of most prominent members of CPP family.
Źródło:
Wiadomości Chemiczne; 2015, 69, 1-2; 9-33
0043-5104
2300-0295
Pojawia się w:
Wiadomości Chemiczne
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Intranasal insulin and cell-penetrating peptides in the treatment of Alzheimer’s disease
Autorzy:
Marciniec, Michał
Kulczyński, Marcin
Nowak, Andrzej
Kwak, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1178799.pdf
Data publikacji:
2017
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
Alzheimer's disease
GLP-1 agonists
anti-diabetic drugs
cell-penetrating peptides
cognitive function
dementia
intranasal insulin
Opis:
Alzheimer’s disease (AD) is the most common cause of dementia and is responsible for up to 75% of the nearly 47 million dementia cases worldwide. AD is the clinical manifestation of toxic β-amyloid and neurofibrillary tangles accumulation caused by altered proteostasis. Due to not fully understood molecular mechanisms of AD only symptomatic treatment is available. Considering that cognitive decline is associated with insulin resistance, metabolic alterations may be the primary causes of the AD and insulin therapy is proposed as a novel approach in AD treatment. Intranasal administration of insulin appears to be a profitable solution for drug delivery to the brain due to blood-brain barrier bypassing, higher bioavailability and the lack of systemic side effects. When applying this method, insulin is sprayed into the nasal cavity, enters the mucosa and is transported along the axon bundles to the brain. Clinical trials of AD treatment with intranasal insulin revealed improvement in cognition, verbal memory and functional status. Notably, enhancement in memory and cognition were observed both in healthy adults and in AD patients and were ApoE ε4-related. The use of cell-penetrating peptides (CPPs) improve cellular uptake of insulin, enhance bioavailability and increase the direct insulin transport into the deeper regions of the brain such as the olfactory bulb and hippocampus. Animal studies revealed beneficial effects on AD symptoms of other molecules applied in connection with CPPs and most of them approve CPPs formulations for use in clinical trials. This review article summarize clinical trials results of intranasal insulin administration in AD treatment and propose the use of CPPs as an additive to conventional and experimental therapies for AD.
Źródło:
World Scientific News; 2017, 90; 138-149
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies